Exodus Point Capital Management, LP Jounce Therapeutics, Inc. Transaction History

Exodus Point Capital Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 19, 2022	SELL	$2.8 - $7.67 $33,499 - $91,763	-11,964 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$6.01 - $8.54 $71,903 - $102,172	11,964 New	11,964 $81,000
Q3 2021 Nov 15, 2021	SELL	$5.04 - $8.73 $131,362 - $227,538	-26,064 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$6.58 - $10.66 $99,943 - $161,914	15,189 Added 139.67%	26,064 $177,000
Q1 2021 May 17, 2021	BUY	$6.73 - $13.87 $73,188 - $150,836	10,875 New	10,875 $112,000

Q3 2020 Nov 16, 2020	SELL	$4.58 - $10.95 $62,920 - $150,431	-13,738 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$4.17 - $7.58 $57,287 - $104,134	13,738 New	13,738 $95,000
Q1 2020 May 15, 2020	SELL	$2.91 - $8.7 $29,391 - $87,870	-10,100 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.81 - $9.21 $28,381 - $93,021	10,100 New	10,100 $88,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.